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trends in the excessive use of -agonist medications. RE-
SULTS: Data from 13,481 patients covered by Pharma-
care PlanC (social assistance–first dollar coverage) or PlanE
(individuals or families exceeding deductible) were ana-
lyzed. In 1996, 1898 patients (14.1%) were high users of
-agonists (12 canisters/yr) compared to 1686 (12.5%)
in 1998 (P  0.001). 1119 patients (59%) who were high
users in 1996 remained high users in 1998, 38.7% of which
continued to use 20 canisters/yr. Of those patients us-
ing  12 canisters in 1996, only 4.9% increased their use
to 12 canisters/yr in 1998. 116 patients prescribed  4
canisters in 1996 substantially increased their use to 12
canisters in 1998. Age was positively associated with the
number of canisters prescribed (r  0.21; P  0.001);
only 4% of patients 19 years used 12 canisters in
1998 compared to 16% of patients  19 yrs. Age was
also associated with increasing use over the 3 years (P 
0.001). CONCLUSIONS: This analysis suggests a trend
in asthma management towards decreasing -agonist
use. However, 10% of -agonist users in this popula-
tion continued to use excessive or increasing amounts of
-agonists despite current treatment guidelines, putting
them at greater risk for -agonist related morbidity and
mortality, and increased health care utilization.
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The Asthma-specific quality of life questionnaire (AQLQ-
NAA) is a 19-item questionnaire and has emphasis on re-
strictions in social, community and cultural activities.
Three domains of the AQLQ-NAA, community and so-
cial restrictions (CSR, 10 items), psychological and im-
pact (PIM, 4 items) and symptoms (SYM, 5 items) have
been identified using principal component analysis. OB-
JECTIVES: The purpose of this study was to identify sig-
nificant predictors of the AQLQ-NAA and each of its do-
mains. METHODS: The AQLQ-NAA was administered
to a sample of 51 adult volunteers with a diagnosis of
asthma at the Albuquerque Indian Hospital and three af-
filiated clinics. Four forward stepwise regression models
were analyzed using total AQLQ-NAA scores and each
domain score separately as the criterion variable. Six pre-
dictors (emergency care visits in the past 6 months, hos-
pitalizations in the past six months, physician visits in the
past six months, corticosteroids used in the past six
months, asthma medications used in the past six months,
and patient gender) were used in the regression models.
RESULTS: Physician visits, hospitalizations and gender
were significant predictors of total AQLQ-NAA scores
(F  10.493, P  0.05, Adjusted R2  0.388) and the
CSR domain scores (F  10.537, P  0.05, Adjusted
R2  0.389). Physician visits and hospitalizations were
significant predictors of the PIM domain scores (F 
13.368, P  0.05, Adjusted R2  0.355). Number of
asthma medications and gender were significant predic-
tors of the SYM domain scores (F  7.107, P  0.05,
Adjusted R2  0.213). CONCLUSIONS: Based on the
predictors for each of the three domains, inherent differ-
ences between the domains were observed. This study
helps further establish evidence of construct validity of
the AQLQ-NAA and its domains.
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OBJECTIVES: The purpose of this study is to evaluate
differences in asthma-related health care resource utiliza-
tion between six months preceding and following the ini-
tiation of fluticasone propionate. METHODS: Adult
asthmatics were identified through administrative medical
and pharmacy claims from an IPA model Health Mainte-
nance Organization. The study population was defined
as any identified asthmatic with continuous enrollment
who had a prescription for fluticasone propionate. Asthma-
related resource utilization was evaluated for differences
in services based on the introduction of fluticasone propi-
onate. RESULTS: A total of 199 asthmatic members
were identified with an average age of 44.7 (12.7) years
old. The majority of patients (60%) were female. There
was an inverse relationship of pharmacy costs to medical
costs from the pre- to post-fluticasone propionate period.
Pharmacy costs increased 61%, while medical costs de-
creased 71 percent. Paired-sample t-tests showed a signif-
icant decrease in the number of hospitalizations, emer-
gency room visits, and diagnostic procedures. Although
pharmacy utilization increased, it resulted in an improved
inhaled corticosteroid to beta-2 agonist ratio of 0.51 to
1.41. The net asthma-related costs declined 35%, repre-
senting a reduction of $296 per asthma study member for
the six-month period. CONCLUSIONS: In summary, the
introduction of fluticasone propionate appeared to have
a substantial impact on resource utilization and cost. Re-
sults support current literature that the use of inhaled
corticosteroids reduces the number of asthma-related
emergency room visits and hospitalizations.
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The US National Institutes of Health (NIH) guidelines
for treating asthma classify patients into four severity lev-
els (severe persistent, moderate persistent, mild persis-
tent, and mild intermittent) based largely on clinically as-
sessed symptoms and physical measurements such as
forced expiratory volume. The guidelines also recom-
mend specific regimens of various asthma medications
for each severity level. OBJECTIVE: To use the medica-
tion regimens recommended by NIH to classify asthma
severity based on patterns of drug use in prescription
claims. METHODS: Using claims data from a large
health insurer in the Northeast US, study patients were
selected in part on the basis of having used zafirlukast
continuously at some point during the 30 months cov-
ered by the database. Of the 780 study patients, 76.8%
could be classified by a computer program into one of the
four NIH severity categories based on their patterns of
asthma drug use as specified in the NIH guidelines. The
remaining 23.2% were classified through review of indi-
vidual claim histories by a nurse abstractor. RESULTS:
60.9% of study patients were classified as having mild
persistent asthma, 22.6% were moderate persistent, 10.4%
were severe persistent, and 6.2% were mild intermittent.
The nurse abstractor also performed a blind review of the
claim histories for a 15% sample of patients who had
been programmatically classified. The two classifications
disagreed in only six cases (i.e., 93.3% agreement, kappa 
0.885, P  0.001). CONCLUSION: Asthma patients can
be classified by severity level based on drug use patterns
in prescription claims with an acceptable level of validity
based on clinical review. This methodology could facilitate
efficient monitoring of asthma severity levels within pa-
tient populations.
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COPD is known to be an underdiagnosed condition.
Stage of disease is an important predictor of diagnosis of
COPD. Previous work has demonstrated that disease
stage, age, gender, race, smoking, cough, and breathless-
ness are drivers of diagnosis for obstructive lung disease
[Coultas et al, ERS 1999]. OBJECTIVES: The purpose of
the study was to determine whether different attributes
or symptoms were responsible for diagnosis at different
stages of disease. METHODS: The US National Health
and Nutrition Examination Survey conducted 1988–1994
measured pulmonary function, respiratory symptoms and
self-reported diagnosis on a representative sample of the
US population. Stage was defined using spirometry, by
ATS definitions. Physical functioning, symptoms ques-
tions, age, gender, race and smoking history were in-
cluded as potential predictors of diagnosis. RESULTS:
Only 19% of individuals with spirometry-defined COPD
reported a history of diagnosed disease. Presence of 2 or
more symptoms (cough, phlegm, sob, wheeze) was the
only indicator which remained in the model for all stages.
The overall OR was 17.5 (11.8, 26.0) Race was highly
significant, OR 20.6 (1.8, 229.3), but only at stage 3.
Physical functioning was significant only in the univari-
ate analysis. CONCLUSIONS: These findings suggest
that symptoms alone are prompting diagnoses of COPD
at all levels of disease. But this population demonstrates
that when disease is defined by spirometry, only a small
proportion of individuals with COPD are actually being
diagnosed.
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Inhaled corticosteroids have revolutionized the treatment
of asthma and have now become the mainstay of therapy
for patients with chronic disease. OBJECTIVE: The pri-
mary objective was to determine the relationship between
inhaled steroid use patterns and asthma-related total
health care cost (e.g. as hospitalizations, emergency room
visits, and pharmacy cost) from a managed care perspec-
tive. METHODS: Retrospective computerized claims
records from a large managed care organization were an-
alyzed. Patients were included if they had an IDC-9 diag-
nosis code for asthma (493.xx) and received at least 1 in-
haled beta agonist during a 3 month identification
period. Patients who received a steroid inhaler during the
identification period were included in the treatment
group and those who never received a steroid inhaler
were included in the control group. All patients were fol-
lowed for a 1 year period, but were excluded if they were
not continuously enrolled in the health plan. RESULTS:
Patients who received a steroid inhaler had a higher phar-
macy cost compared to those who did not ($453 versus
$894, P  0.001). In a multivariate regression analysis
controlling for potential confounding factors such as age,
gender, benefit design, disease severity, and number of
comorbidities, pharmacy cost remained higher in the ste-
roid inhaler group (Beta  $428, P  0.0001). In a simi-
lar regression analysis, total health care cost was lower in
the steroid inhaler group (Beta  $1,892, P  0.001).
Furthermore, the use of steroid inhalers was associated
with less utilization of methylprednisolone dose packs.
CONCLUSION: The higher cost of inhaled steroid use
appears to be offset by a reduction in hospital and emer-
gency room visit cost.
